Opening of New Manufacturing Facility to Meet Expanding Demand for Topical Wound Oxygen (TWO2) Therapy Devices
We are delighted to invest in this new facility that will allow us to more effectively ramp up production of our unique multi-modality wound care therapy product line to meet our continually expanding supply needs,” stated Dr. Mike Griffiths, Chief Executive Officer and President of AOTI.
Breakthrough Randomized Controlled Trial Demonstrating TWO2 Efficacy in Healing Diabetic Foot Ulcers unveiled at the American Diabetes Association 78th Scientific Sessions Conference
This breakthrough study unequivocally demonstrates at the highest scientific level the efficacy of Cyclical Pressure Topical Wound Oxygen Therapy in healing Diabetic Foot Ulcers” stated Dr. Robert Frykberg, the Chief Principle Investigator of the study.
Unprecedented Study Results Demonstrating Topical Wound Oxygen Effectiveness Presented at Major Wound Care Conferences
The study was a two-year retrospective review of 71 patients with a total of 115 wounds treated by a Veterans Affairs hospital in Chicago that prescribed cyclical pressurized TWO2 therapy for use at home.
AOTI Inc. announced today that its fully owned USA-operating subsidiary, Advanced Oxygen Therapy Inc., has recently opened a New York City Office in Yonkers, New York to support the ever-increasing usage of its unique Topical Wound Oxygen (TWO2) homecare therapy. This new East Coast location has also been approved by the Accreditation Commission for Health Care (ACHC) under the company’s DMEPOS accreditation for Home/Durable Medical Equipment Services.